Device‐related pressure injury (DRPI) is a serious problem that is affecting professionals working on the front lines against COVID‐19 due to the prolonged use of personal protective equipment (PPE). In addition to the physical and psychological integrity of professionals, these injuries can compromise the quality of care. Therefore, using technologies to prevent this adverse effect is an urgent matter. This is a parallel two‐arm randomized clinical trial without the use of a control group to compare the use of foam and extra‐thin hydrocolloid in preventing DRPI associated with the use of PPE by health professionals working on the front lines against coronavirus. In total, 88 professionals were divided into two groups: foam and hydrocolloid. Data were collected using two instruments and related to demographic and professional characteristics and skin evaluation. Each volunteer received one of the dressings, both with the same dimensions and arranged over similar regions, and data were gathered at baseline and after 6 or 12 hours. Descriptive and inferential analytic statistical methods were used; the significance level adopted was 5%. No participant developed DRPI, but four areas with hyperemia were observed in the foam group (two in the forehead, one in the cheeks, and one in the nose bridge), as well as four areas with hyperemia in the hydrocolloid group (two in the nose bridge, one in the right ear, and one in the left ear). There was no difference between the groups regarding skin conditions and discomfort (P > .05). The average cost obtained was $ 5.8/person and $ 4.4/person in the foam group and the hydrocolloid group, respectively, considering the dressing measurements. The results show that foam and extra‐thin hydrocolloid were effective in preventing DRPI associated with the use of PPE.
Inflammatory reactions in the Bacillus Calmette-Guérin (BCG) inoculation scar site have been previously described, in association with viral infections. The inflammation of the scar in association with other vaccines has been described with the flu vaccine and, more recently, after the second dose of mRNA anti-SARS-CoV-2 vaccines (mRNA-1273 e BNT162b2), in two healthcare workers. We present the case of a 27-year-old female, without a relevant past medical history, including no previous SARS-CoV-2 infection, and with inflammation of the BCG scar eight days after the first dose of the mRNA anti-SARS-CoV-2 vaccine. Pharmacovigilance and the notification of adverse events should be encouraged, as a way of warding off hesitation in this process.
Objetivo: avaliar a implementação de um programa de capacitação para medidas de prevenção de lesão por pressão por meio de instrumentos validados. Metodologia: estudo quase-experimental desenvolvido em quatro etapas: validação de conteúdo de um instrumento de auditoria para a avaliação da implementação de medidas de prevenção de lesão por pressão; auditoria para a avaliação da implementação das medidas; intervenção educativa com validação de face de um questionário para avaliar a aprendizagem; repetição da auditoria dois meses após a intervenção educativa. Resultados: a validação alcançou porcentagem de concordância entre os especialistas superior a 0,9. Na primeira auditoria, a conformidade na implementação das medidas foi de 65,1%. A nota da avaliação de aprendizagem antes da intervenção foi 7,99 e, após, 8,45 (p<0,0001). Na segunda auditoria, a conformidade na implementação das medidas foi de 56,2%. Conclusão: a implementação de um programa de capacitação para medidas de prevenção de lesão por pressão contribuiu para aumentar o nível de conhecimento teórico dos participantes, entretanto, não houve a translação do conhecimento adquirido para a prática clínica. A validação dos instrumentos foi satisfatória.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.